Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PROTAC-mediated degradation of class I histone deacetylase enzymes in corepressor complexes
Joshua P. Smalley, Grace E. Adams, Christopher J. Millard, et al.
Chemical Communications (2020) Vol. 56, Iss. 32, pp. 4476-4479
Open Access | Times Cited: 94

Showing 1-25 of 94 citing articles:

Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Terence C. S. Ho, Alex H. Y. Chan, A. Ganesan
Journal of Medicinal Chemistry (2020) Vol. 63, Iss. 21, pp. 12460-12484
Open Access | Times Cited: 569
PROTACs: An Emerging Therapeutic Modality in Precision Medicine
Dhanusha A. Nalawansha, Craig M. Crews
Cell chemical biology (2020) Vol. 27, Iss. 8, pp. 998-1014
Open Access | Times Cited: 335
Current strategies for the design of PROTAC linkers: a critical review
Robert I. Troup, Charlene Fallan, Matthias G. J. Baud
Exploration of Targeted Anti-tumor Therapy (2020) Vol. 1, Iss. 5
Open Access | Times Cited: 251
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Xinyi Li, Wenchen Pu, Qingquan Zheng, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 187
Targeted protein degradation: A promise for undruggable proteins
Kusal T. G. Samarasinghe, Craig M. Crews
Cell chemical biology (2021) Vol. 28, Iss. 7, pp. 934-951
Open Access | Times Cited: 186
PROTACs: great opportunities for academia and industry (an update from 2020 to 2021)
Ming He, Chao-Guo Cao, Zhihao Ni, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 168
Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges
Shenxin Zeng, Wenhai Huang, Xiaoliang Zheng, et al.
European Journal of Medicinal Chemistry (2020) Vol. 210, pp. 112981-112981
Closed Access | Times Cited: 165
An overview of PROTACs: a promising drug discovery paradigm
Liu Zi, Mingxing Hu, Yang Yu, et al.
Molecular Biomedicine (2022) Vol. 3, Iss. 1
Open Access | Times Cited: 153
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future Perspectives
Robert Jenke, Nina Reßing, Finn K. Hansen, et al.
Cancers (2021) Vol. 13, Iss. 4, pp. 634-634
Open Access | Times Cited: 137
Targeted degradation of the enhancer lysine acetyltransferases CBP and p300
Raghu Vannam, Jan Fehmi Sayılgan, Samuel Ojeda, et al.
Cell chemical biology (2021) Vol. 28, Iss. 4, pp. 503-514.e12
Open Access | Times Cited: 124
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang Tao, Fengli Wang, Reham M. Elhassan, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 13, Iss. 6, pp. 2425-2463
Open Access | Times Cited: 83
Strategies for designing proteolysis targeting chimaeras (PROTACs)
Shipeng He, Guoqiang Dong, Junfei Cheng, et al.
Medicinal Research Reviews (2022) Vol. 42, Iss. 3, pp. 1280-1342
Closed Access | Times Cited: 73
Annual review of PROTAC degraders as anticancer agents in 2022
Xiao Wang, Zhao-Long Qin, Na Li, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116166-116166
Closed Access | Times Cited: 54
HDAC-targeting epigenetic modulators for cancer immunotherapy
Binbin Cheng, Wei Pan, Yao Xiao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116129-116129
Closed Access | Times Cited: 31
Developments of CRBN-based PROTACs as potential therapeutic agents
Chao Wang, Yujing Zhang, Yudong Wu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 225, pp. 113749-113749
Closed Access | Times Cited: 96
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Yonghan He, Sajid Khan, Zhiguang Huo, et al.
Journal of Hematology & Oncology (2020) Vol. 13, Iss. 1
Open Access | Times Cited: 92
Discovery of histone deacetylase 3 (HDAC3)-specific PROTACs
Yufeng Xiao, Jia Wang, Lisa Zhao, et al.
Chemical Communications (2020) Vol. 56, Iss. 68, pp. 9866-9869
Open Access | Times Cited: 91
Chemo-proteomics exploration of HDAC degradability by small molecule degraders
Yuan Xiong, Katherine A. Donovan, Nicholas A. Eleuteri, et al.
Cell chemical biology (2021) Vol. 28, Iss. 10, pp. 1514-1527.e4
Open Access | Times Cited: 67
A bibliometric analysis of PROTAC from 2001 to 2021
Deping Li, Dongmin Yu, Yan Li, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114838-114838
Closed Access | Times Cited: 65
Medicinal chemistry updates of novel HDACs inhibitors (2020 to present)
Xingrui He, Zi Hui, Li Xu, et al.
European Journal of Medicinal Chemistry (2021) Vol. 227, pp. 113946-113946
Closed Access | Times Cited: 57
Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells
Joshua P. Smalley, India M. Baker, Wiktoria A. Pytel, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 7, pp. 5642-5659
Open Access | Times Cited: 56
HDAC Inhibitors: Innovative Strategies for Their Design and Applications
Mateusz Daśko, Beatriz de Pascual‐Teresa, Irene Ortín, et al.
Molecules (2022) Vol. 27, Iss. 3, pp. 715-715
Open Access | Times Cited: 44
Solid-Phase Synthesis of Cereblon-Recruiting Selective Histone Deacetylase 6 Degraders (HDAC6 PROTACs) with Antileukemic Activity
Laura Sinatra, Jing Yang, Julian Schliehe‐Diecks, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 24, pp. 16860-16878
Open Access | Times Cited: 42
Selective degradation of histone deacetylase 8 mediated by a proteolysis targeting chimera (PROTAC)
Jiranan Chotitumnavee, Yasunobu Yamashita, Yukari Takahashi, et al.
Chemical Communications (2022) Vol. 58, Iss. 29, pp. 4635-4638
Closed Access | Times Cited: 40
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
Xiaopeng Peng, Zhihao Hu, Limei Zeng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 2, pp. 533-578
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top